Related Organization(s)

You just read:

CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis (RA)

News provided by

Eli Lilly and Company

Dec 16, 2016, 07:48 ET